Concepts (256)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA Repair | 14 | 2022 | 188 | 4.150 |
Why?
|
| Breast Neoplasms | 16 | 2022 | 1502 | 1.950 |
Why?
|
| Skin Neoplasms | 4 | 2011 | 159 | 1.020 |
Why?
|
| Carcinoma, Basal Cell | 4 | 2011 | 20 | 1.000 |
Why?
|
| DNA, Neoplasm | 2 | 2021 | 92 | 0.930 |
Why?
|
| Lymphocytes | 2 | 2020 | 118 | 0.770 |
Why?
|
| Overweight | 1 | 2022 | 247 | 0.720 |
Why?
|
| DNA Methylation | 3 | 2021 | 325 | 0.690 |
Why?
|
| DNA Damage | 3 | 2012 | 352 | 0.630 |
Why?
|
| Case-Control Studies | 10 | 2018 | 1130 | 0.630 |
Why?
|
| Vitamin D | 1 | 2020 | 196 | 0.620 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2011 | 178 | 0.620 |
Why?
|
| MicroRNAs | 2 | 2023 | 426 | 0.530 |
Why?
|
| Receptors, Estrogen | 1 | 2016 | 156 | 0.510 |
Why?
|
| Aged | 12 | 2021 | 6741 | 0.480 |
Why?
|
| Middle Aged | 15 | 2021 | 10129 | 0.450 |
Why?
|
| Gene Expression | 1 | 2016 | 674 | 0.440 |
Why?
|
| Neoplasm Staging | 4 | 2021 | 275 | 0.440 |
Why?
|
| Epigenesis, Genetic | 3 | 2021 | 219 | 0.430 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2021 | 807 | 0.430 |
Why?
|
| BRCA2 Protein | 4 | 2019 | 37 | 0.430 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 2 | 2013 | 4 | 0.430 |
Why?
|
| Adult | 13 | 2022 | 11712 | 0.420 |
Why?
|
| Female | 22 | 2022 | 20969 | 0.410 |
Why?
|
| Humans | 35 | 2023 | 37093 | 0.400 |
Why?
|
| Fanconi Anemia | 1 | 2011 | 12 | 0.400 |
Why?
|
| Risk Factors | 7 | 2022 | 3562 | 0.360 |
Why?
|
| Melanoma | 1 | 2011 | 96 | 0.360 |
Why?
|
| Germ-Line Mutation | 2 | 2019 | 57 | 0.340 |
Why?
|
| Ultraviolet Rays | 2 | 2011 | 117 | 0.330 |
Why?
|
| Antineoplastic Agents | 6 | 2014 | 803 | 0.320 |
Why?
|
| Up-Regulation | 1 | 2011 | 513 | 0.320 |
Why?
|
| Organometallic Compounds | 4 | 2010 | 73 | 0.320 |
Why?
|
| Puerto Rico | 10 | 2021 | 1378 | 0.320 |
Why?
|
| Genes, p53 | 1 | 2007 | 25 | 0.310 |
Why?
|
| Receptors, Cell Surface | 1 | 2007 | 144 | 0.290 |
Why?
|
| BRCA1 Protein | 3 | 2019 | 48 | 0.280 |
Why?
|
| Logistic Models | 3 | 2016 | 923 | 0.240 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2004 | 29 | 0.240 |
Why?
|
| Ferrous Compounds | 2 | 2014 | 20 | 0.230 |
Why?
|
| Genetic Variation | 2 | 2018 | 387 | 0.210 |
Why?
|
| Ciguatera Poisoning | 1 | 2002 | 3 | 0.210 |
Why?
|
| Oxocins | 1 | 2002 | 3 | 0.210 |
Why?
|
| Prostatic Neoplasms | 2 | 2021 | 935 | 0.210 |
Why?
|
| Foodborne Diseases | 1 | 2002 | 22 | 0.200 |
Why?
|
| Acute Disease | 1 | 2002 | 147 | 0.200 |
Why?
|
| Biological Clocks | 1 | 2021 | 53 | 0.200 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2020 | 35 | 0.180 |
Why?
|
| Norepinephrine | 1 | 2020 | 110 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2019 | 628 | 0.180 |
Why?
|
| Oncogenes | 1 | 2019 | 43 | 0.180 |
Why?
|
| Triamcinolone Acetonide | 1 | 2019 | 2 | 0.170 |
Why?
|
| Keloid | 1 | 2019 | 3 | 0.170 |
Why?
|
| Aged, 80 and over | 4 | 2014 | 2379 | 0.170 |
Why?
|
| Neuromuscular Agents | 1 | 2019 | 4 | 0.170 |
Why?
|
| Ovarian Neoplasms | 2 | 2020 | 312 | 0.160 |
Why?
|
| Glucocorticoids | 1 | 2019 | 86 | 0.160 |
Why?
|
| Body Mass Index | 1 | 2022 | 854 | 0.160 |
Why?
|
| Genes, BRCA2 | 1 | 2018 | 5 | 0.160 |
Why?
|
| Young Adult | 3 | 2019 | 4268 | 0.140 |
Why?
|
| Regression Analysis | 1 | 2017 | 455 | 0.140 |
Why?
|
| Male | 12 | 2021 | 20025 | 0.130 |
Why?
|
| Receptors, Progesterone | 1 | 2016 | 81 | 0.130 |
Why?
|
| Genetic Testing | 1 | 2015 | 75 | 0.130 |
Why?
|
| Subcellular Fractions | 1 | 2005 | 77 | 0.130 |
Why?
|
| Photosensitizing Agents | 1 | 2005 | 49 | 0.120 |
Why?
|
| Receptor, erbB-2 | 1 | 2016 | 133 | 0.120 |
Why?
|
| Porphyrins | 1 | 2005 | 55 | 0.120 |
Why?
|
| DNA-Binding Proteins | 2 | 2019 | 539 | 0.120 |
Why?
|
| Obesity | 1 | 2022 | 1067 | 0.120 |
Why?
|
| Fluorescent Dyes | 1 | 2005 | 181 | 0.120 |
Why?
|
| Nerve Growth Factors | 1 | 2014 | 33 | 0.120 |
Why?
|
| Pilot Projects | 3 | 2021 | 661 | 0.120 |
Why?
|
| Regional Health Planning | 1 | 2013 | 14 | 0.120 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2014 | 43 | 0.120 |
Why?
|
| DNA Repair Enzymes | 1 | 2013 | 20 | 0.110 |
Why?
|
| Phenotype | 1 | 2016 | 689 | 0.110 |
Why?
|
| Minority Health | 1 | 2013 | 88 | 0.110 |
Why?
|
| ROC Curve | 1 | 2012 | 138 | 0.110 |
Why?
|
| Genetic Markers | 1 | 2012 | 142 | 0.100 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 461 | 0.100 |
Why?
|
| Ergocalciferols | 1 | 2011 | 6 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 515 | 0.100 |
Why?
|
| Fanconi Anemia Complementation Group L Protein | 1 | 2011 | 2 | 0.100 |
Why?
|
| Fanconi Anemia Complementation Group C Protein | 1 | 2011 | 3 | 0.100 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2011 | 10 | 0.100 |
Why?
|
| Fanconi Anemia Complementation Group D2 Protein | 1 | 2011 | 9 | 0.100 |
Why?
|
| CpG Islands | 2 | 2021 | 97 | 0.100 |
Why?
|
| Apoproteins | 2 | 2008 | 16 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 562 | 0.100 |
Why?
|
| Societies, Scientific | 1 | 2010 | 8 | 0.090 |
Why?
|
| Transferrin | 2 | 2008 | 40 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 306 | 0.090 |
Why?
|
| Mutagens | 1 | 2010 | 69 | 0.090 |
Why?
|
| Steroids | 1 | 2010 | 43 | 0.090 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2010 | 51 | 0.090 |
Why?
|
| Estrogens | 1 | 2011 | 202 | 0.090 |
Why?
|
| Molybdenum | 1 | 2009 | 14 | 0.090 |
Why?
|
| Colonic Neoplasms | 2 | 2011 | 186 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 935 | 0.080 |
Why?
|
| Serum Albumin | 1 | 2009 | 50 | 0.080 |
Why?
|
| Chelating Agents | 1 | 2009 | 57 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 560 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 767 | 0.080 |
Why?
|
| Cell Line, Tumor | 5 | 2020 | 2231 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2013 | 494 | 0.080 |
Why?
|
| Epinephrine | 2 | 2020 | 36 | 0.080 |
Why?
|
| Titanium | 1 | 2008 | 36 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2013 | 534 | 0.080 |
Why?
|
| Age of Onset | 1 | 2007 | 100 | 0.080 |
Why?
|
| Health Status Disparities | 1 | 2013 | 642 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2009 | 1039 | 0.070 |
Why?
|
| Models, Molecular | 3 | 2019 | 808 | 0.070 |
Why?
|
| Luciferases | 2 | 2004 | 63 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2012 | 753 | 0.070 |
Why?
|
| Time Factors | 4 | 2007 | 1742 | 0.070 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2004 | 36 | 0.060 |
Why?
|
| Epidemiologic Studies | 1 | 2004 | 31 | 0.060 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2003 | 14 | 0.060 |
Why?
|
| Genetics, Population | 2 | 2015 | 100 | 0.060 |
Why?
|
| Neoplasms | 1 | 2013 | 1103 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2009 | 1198 | 0.060 |
Why?
|
| Latin America | 2 | 2015 | 45 | 0.060 |
Why?
|
| Age Distribution | 1 | 2003 | 225 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2003 | 215 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2012 | 2026 | 0.050 |
Why?
|
| Ligands | 3 | 2009 | 349 | 0.050 |
Why?
|
| Copper Sulfate | 1 | 2002 | 5 | 0.050 |
Why?
|
| Ciguatoxins | 1 | 2002 | 2 | 0.050 |
Why?
|
| Marine Toxins | 1 | 2002 | 13 | 0.050 |
Why?
|
| Tropical Climate | 1 | 2002 | 20 | 0.050 |
Why?
|
| Ascorbic Acid | 1 | 2002 | 66 | 0.050 |
Why?
|
| Incidence | 1 | 2004 | 922 | 0.050 |
Why?
|
| Argentina | 2 | 2012 | 12 | 0.050 |
Why?
|
| Biological Assay | 1 | 2002 | 59 | 0.050 |
Why?
|
| Neurotoxins | 1 | 2002 | 57 | 0.050 |
Why?
|
| Gastrointestinal Diseases | 1 | 2002 | 42 | 0.050 |
Why?
|
| Structure-Activity Relationship | 2 | 2014 | 409 | 0.050 |
Why?
|
| Genotype | 2 | 2013 | 730 | 0.050 |
Why?
|
| DNA Glycosylases | 1 | 2019 | 16 | 0.040 |
Why?
|
| Cisplatin | 1 | 2020 | 72 | 0.040 |
Why?
|
| Point Mutation | 1 | 2019 | 93 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2019 | 83 | 0.040 |
Why?
|
| Pruritus | 1 | 2019 | 3 | 0.040 |
Why?
|
| Injections, Intralesional | 1 | 2019 | 11 | 0.040 |
Why?
|
| Mutation | 2 | 2015 | 1095 | 0.040 |
Why?
|
| Spectrum Analysis | 2 | 2010 | 54 | 0.040 |
Why?
|
| Molecular Conformation | 2 | 2010 | 152 | 0.040 |
Why?
|
| Histones | 1 | 2020 | 190 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2019 | 286 | 0.040 |
Why?
|
| Disease Progression | 1 | 2021 | 601 | 0.040 |
Why?
|
| Infant | 1 | 2002 | 1046 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 227 | 0.040 |
Why?
|
| Animals | 7 | 2010 | 15081 | 0.040 |
Why?
|
| Introns | 1 | 2018 | 75 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2002 | 1418 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 626 | 0.040 |
Why?
|
| Hexanols | 1 | 1975 | 2 | 0.030 |
Why?
|
| Pain | 1 | 2019 | 251 | 0.030 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1975 | 31 | 0.030 |
Why?
|
| Caribbean Region | 1 | 2015 | 69 | 0.030 |
Why?
|
| Acetylcholinesterase | 1 | 1975 | 55 | 0.030 |
Why?
|
| Aminoacridines | 1 | 2005 | 1 | 0.030 |
Why?
|
| Acridine Orange | 1 | 2005 | 2 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1975 | 52 | 0.030 |
Why?
|
| Carbocyanines | 1 | 2005 | 14 | 0.030 |
Why?
|
| Cardiolipins | 1 | 2005 | 11 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2015 | 195 | 0.030 |
Why?
|
| Choline | 1 | 1975 | 59 | 0.030 |
Why?
|
| Micronucleus Tests | 1 | 2014 | 10 | 0.030 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2005 | 57 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2005 | 105 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2019 | 1369 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 1975 | 196 | 0.030 |
Why?
|
| Endoplasmic Reticulum | 1 | 2005 | 105 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 1975 | 177 | 0.030 |
Why?
|
| Southeastern United States | 1 | 2013 | 49 | 0.030 |
Why?
|
| Interinstitutional Relations | 1 | 2013 | 38 | 0.030 |
Why?
|
| Child | 1 | 2002 | 3131 | 0.030 |
Why?
|
| Community Networks | 1 | 2013 | 108 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2013 | 170 | 0.030 |
Why?
|
| Protein Binding | 2 | 2011 | 972 | 0.030 |
Why?
|
| Heterozygote | 1 | 2012 | 93 | 0.030 |
Why?
|
| Adolescent | 2 | 2002 | 5363 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 448 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2012 | 188 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2012 | 100 | 0.020 |
Why?
|
| Mitochondria | 1 | 2005 | 487 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2012 | 126 | 0.020 |
Why?
|
| Estrogen Receptor alpha | 1 | 2011 | 111 | 0.020 |
Why?
|
| Brazil | 1 | 2010 | 64 | 0.020 |
Why?
|
| Oxygen | 2 | 2009 | 207 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 739 | 0.020 |
Why?
|
| Quantum Theory | 1 | 2010 | 78 | 0.020 |
Why?
|
| Titrimetry | 1 | 2009 | 8 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 1067 | 0.020 |
Why?
|
| Electrochemical Techniques | 1 | 2009 | 22 | 0.020 |
Why?
|
| Spectrophotometry | 1 | 2009 | 70 | 0.020 |
Why?
|
| Environment | 1 | 2010 | 138 | 0.020 |
Why?
|
| Solubility | 1 | 2009 | 118 | 0.020 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2009 | 132 | 0.020 |
Why?
|
| Pregnancy | 1 | 2013 | 1549 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 2008 | 36 | 0.020 |
Why?
|
| HT29 Cells | 1 | 2008 | 45 | 0.020 |
Why?
|
| Solutions | 1 | 2008 | 62 | 0.020 |
Why?
|
| Rats | 4 | 1975 | 3483 | 0.020 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2008 | 98 | 0.020 |
Why?
|
| Thiazoles | 1 | 2008 | 74 | 0.020 |
Why?
|
| Drug Stability | 1 | 2008 | 116 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2009 | 492 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2007 | 71 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2008 | 289 | 0.020 |
Why?
|
| Tetanus | 1 | 1976 | 3 | 0.020 |
Why?
|
| Methyltyrosines | 1 | 1975 | 1 | 0.020 |
Why?
|
| Trypanosoma | 1 | 1975 | 8 | 0.020 |
Why?
|
| Cell Survival | 1 | 2009 | 864 | 0.020 |
Why?
|
| Adrenalectomy | 1 | 1975 | 25 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2007 | 207 | 0.020 |
Why?
|
| Digitoxin | 1 | 1975 | 7 | 0.020 |
Why?
|
| Respiration | 1 | 1976 | 58 | 0.020 |
Why?
|
| Carbon Dioxide | 1 | 1976 | 77 | 0.020 |
Why?
|
| United States | 1 | 2015 | 4223 | 0.020 |
Why?
|
| Microsomes, Liver | 1 | 1975 | 70 | 0.020 |
Why?
|
| Corpus Striatum | 1 | 1975 | 104 | 0.020 |
Why?
|
| Dopamine | 1 | 1975 | 245 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2002 | 113 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 307 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 502 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1976 | 364 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1975 | 58 | 0.010 |
Why?
|
| Phenoxybenzamine | 1 | 1975 | 2 | 0.010 |
Why?
|
| Phosphorus Radioisotopes | 1 | 1975 | 9 | 0.010 |
Why?
|
| Hexokinase | 1 | 1975 | 10 | 0.010 |
Why?
|
| Propranolol | 1 | 1975 | 18 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 1975 | 55 | 0.010 |
Why?
|
| Mathematics | 1 | 1975 | 48 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 1975 | 103 | 0.010 |
Why?
|
| Phosphorus | 1 | 1975 | 68 | 0.010 |
Why?
|
| Kinetics | 1 | 1975 | 708 | 0.010 |
Why?
|
| Binding Sites | 1 | 1975 | 651 | 0.010 |
Why?
|
| Partial Pressure | 1 | 1976 | 9 | 0.000 |
Why?
|
| Benserazide | 1 | 1975 | 1 | 0.000 |
Why?
|
| Brocresine | 1 | 1975 | 1 | 0.000 |
Why?
|
| Liver Glycogen | 1 | 1975 | 1 | 0.000 |
Why?
|
| p-Hydroxyamphetamine | 1 | 1975 | 1 | 0.000 |
Why?
|
| Homovanillic Acid | 1 | 1975 | 10 | 0.000 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 1 | 1975 | 27 | 0.000 |
Why?
|
| Biological Transport, Active | 1 | 1975 | 26 | 0.000 |
Why?
|
| Blood | 1 | 1976 | 37 | 0.000 |
Why?
|
| Digitoxigenin | 1 | 1975 | 4 | 0.000 |
Why?
|
| Hydroxylation | 1 | 1975 | 15 | 0.000 |
Why?
|
| Chromatography, Thin Layer | 1 | 1975 | 37 | 0.000 |
Why?
|
| NADP | 1 | 1975 | 38 | 0.000 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 1975 | 78 | 0.000 |
Why?
|
| Tyrosine | 1 | 1975 | 118 | 0.000 |
Why?
|
| Glucose | 1 | 1975 | 230 | 0.000 |
Why?
|